Replies to post #138189 on Biotech Values

[DewDiligence]

Subcutaneous Actemra is non-inferior to IV formulation in ACR20 endpoint at 24 weeks:

http://finance.yahoo.com/news/genentech-reports-positive-study-actemra-050000943.html